Brokers Set Expectations for Inventiva FY2025 Earnings

Key Points

• HC Wainwright predicts that Inventiva will report an earnings per share (EPS) of ($1.44) for FY2025, improving from the current consensus estimate of ($2.08) EPS.
• Several analysts have given Inventiva a "Buy" rating, with price targets ranging from $13.00 to $26.00, indicating strong optimism about the stock’s future performance.
• Inventiva’s stock has shown volatility with a past year trading range between $1.53 and $6.50, opening at $5.60 recently.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) - Investment analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Inventiva in a research note issued to investors on Wednesday, September 3rd. HC Wainwright analyst A. Ghosh expects that the company will earn ($1.44) per share for the year. HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Inventiva's current full-year earnings is ($2.08) per share. HC Wainwright also issued estimates for Inventiva's FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($2.43) EPS, FY2028 earnings at $0.49 EPS and FY2029 earnings at $3.19 EPS.

IVA has been the subject of a number of other reports. Piper Sandler began coverage on Inventiva in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price target for the company. Guggenheim increased their price target on Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $14.83.

Inventiva Stock Up 2.8%

Shares of IVA traded up $0.15 during trading hours on Friday, reaching $5.51. The stock had a trading volume of 23,239 shares, compared to its average volume of 23,432. Inventiva has a 12 month low of $1.53 and a 12 month high of $6.50. The company's 50-day moving average is $3.99 and its two-hundred day moving average is $3.51.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.